Smoking increases risk of second primary lung cancer (SPLC)
the ONA take:
According to a new study published in the journal Cancer, researchers have found that increased tobacco exposure is linked with a higher risk of developing second primary lung cancers (SPLCs) and current smokers have an elevated risk of mortality compared with former and never-smokers.
For the study, researchers identified 1,484 patients who underwent surgery for non-small cell lung cancer (NSCLC) bettween 1995 and 2008. The researchers then analyzed the rates of SPLC based on smoking status and history and examined overall survival, local control, distant metastases, and postoperative mortality.
Of the 1,484 patients identified, 98 were never-smokers. The researchers found that the incidence of SPLC at 3, 5, and 8 years was 5%, 8%, and 16%, respectively. Of the never-smokers, only 1 developed an SPLC. Analyses showed that smoking history was the only independent risk factor for developing SPLC (HR, 1.08; 95% CI: 1.02-1.16, P = 0.031), which results in an 8% increased risk for developing the disease per 10 pack-year history.
Researchers found similar rates of local control and distant metastases among all smoking smoking statuses. Never-smokers had a decreased postoperative mortality compared with ever-smokers.
Increased tobacco exposure is linked with a higher risk of developing second primary lung cancers.
The objective of the current study was to determine the effect of smoking on the development of second primary lung cancers (SPLCs) and other clinical outcomes after surgery for non–small cell lung cancer (NSCLC). SPLCs are rare in never–smokers.
Increasing tobacco exposure is associated with a higher risk of SPLC in patients with a history of smoking. Current smokers have an increased risk of mortality whereas former and never–smokers have comparable survival.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|